Voyager Therapeutics Inc VYGR

NAS: VYGR | ISIN: US92915B1061   3/05/2024
8,810 USD (+3,28%)
(+3,28%)   3/05/2024
Grafiek Voyager Therapeutics Inc Grafiek Voyager Therapeutics Inc

Voyager Therapeutics Inc in het nieuws

18 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Voyager Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - VYGR · Persbericht

12 maart 2021 · INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm · Persbericht

12 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Voyager Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - VYGR · Persbericht

9 maart 2021 · ROSEN, A LEADING LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors With Large Losses to Secure Counsel Before Important March 24 Deadline - VYGR · Persbericht

3 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Voyager Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - VYGR · Persbericht

26 februari 2021 · VYGR BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important March 24 Deadline - VYGR · Persbericht

25 februari 2021 · Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates · Persbericht

25 februari 2021 · INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm · Persbericht

19 februari 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Voyager Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - VYGR · Persbericht

18 februari 2021 · Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference · Persbericht

Profiel Voyager Therapeutics Inc

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.voyagertherapeutics.com

Hoofdzetel: Cambridge, Massachusetts vlag Verenigde Staten

CEO: G. Andre Turenne

Werknemers: 149

Aandelen Voyager Therapeutics Inc

Beurswaarde: 463,93 miljoen USD

Effecten: 54,39 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 1,16

Mijn selecties